Makes for interesting reading:Systematic analysis of off-labeland off-guideline cancer therapy usagein a real-world cohort of 165,912 US patientsRuishan Liu,1,5 Lisa Wang,2,6 Shemra Rizzo,2,6 Marius Rene Garmhausen,2,6 Navdeep Pal,2,6 Sarah Waliany,3,6 Sarah McGough,2 Yvonne G. Lin,2 Zhi Huang,4 Joel Neal,3 Ryan Copping,2,* and James Zou1,4,7,*1Department of Electrical Engineering, Stanford University, Stanford, CA, USA2Genentech, South San Francisco, CA, USA3School of Medicine, Stanford University, Stanford, CA, USA4Department of Biomedical Data Science, Stanford University, Stanford, CA, USA 5Department of Computer Science, University of Southern California, Los Angeles, CA, USA 6These authors contributed equally7Lead contact*Correspondence: [email protected] (R.C.), [email protected] (J.Z.) https://doi.org/10.1016/j.xcrm.2024.101444SUMMARYPatients with cancer may be given treatments that are not officially approved (off-label) or recommended by guidelines (off-guideline). Here we present a data science framework to systematically characterize off-label and off-guideline usages using real-world data from de-identified electronic health records (EHR). We analyze treatment patterns in 165,912 US patients with 14 common cancer types. We find that 18.6% and 4.4% of patients have received at least one line of off-label and off-guideline cancer drugs, respectively. Pa- tients with worse performance status, in later lines, or treated at academic hospitals are significantly more likely to receive off-label and off-guideline drugs. To quantify how predictable off-guideline usage is, we developed machine learning models to predict which drug a patient is likely to receive based on their clinical characteristics and previous treatments. Finally, we demonstrate that our systematic analyses generate hy- potheses about patients’ response to treatments.https://www.cell.com/cell-reports-medicine/pdf/S2666-3791(24)00067-3.pdf
The noble aspirations of many when faced with the abyss are thrown out the window and their own survival becomes paramount.
However leaving all that to one side I understood that unlike most cancer treatments the affordability of CF33 has always been spoken about by Professor Fong greatly increasing the opportunities for its off label use.
My opinion only DYOR
Fact Finder
- Forums
- ASX - By Stock
- IMU
- Media Thread
Media Thread, page-14645
-
-
- There are more pages in this discussion • 901 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.2M |
Open | High | Low | Value | Volume |
5.2¢ | 5.2¢ | 5.0¢ | $1.098M | 21.50M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
97 | 7481668 | 5.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.1¢ | 1703097 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
97 | 7481668 | 0.050 |
26 | 3019321 | 0.049 |
24 | 1822995 | 0.048 |
10 | 2942679 | 0.047 |
15 | 1604916 | 0.046 |
Price($) | Vol. | No. |
---|---|---|
0.051 | 1703097 | 4 |
0.052 | 4137566 | 15 |
0.053 | 2218416 | 9 |
0.054 | 1549915 | 8 |
0.055 | 1499783 | 10 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online